Evidence map›Paper›PMID 35587939›Full record

ArticlePloS one2022

Clinical epidemiology and high genetic diversity amongst Cryptococcus spp. isolates infecting people living with HIV in Kinshasa, Democratic Republic of Congo.

Bive Zono Bive, Rosalie Sacheli, Hippolyte Situakibanza Nani-Tuma, Pius Kabututu Zakayi, Alex Ka, Marcel Mbula Mambimbi, Gaultier Muendele, Raphael Boreux, Nicole Landu, Celestin Nzanzu Mudogo and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Sequence Types ofPathogens (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Article
  5. The hypervirulent Type-1/Type-17 phenotype ofInfection and immunity · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Exposure ofPathogens (Basel, Switzerland) · 2023
    Article
  11. What's New inJournal of fungi (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Bive Zono BiveFaculty of Medicine, Department of Basic Sciences, Molecular Biology Service, University of Kinshasa, Kinshasa, The Democratic Republic of Congo.ORCID 0000-0002-0084-5068
Rosalie SacheliCentre for Interdisciplinary Research on Medicines, University of Liege, Liege, Belgium.
Hippolyte Situakibanza Nani-TumaFaculty of Medicine, Department of Internal Medicine/Department of Tropical Medicine, Infectious Diseases Service, University of Kinshasa, Kinshasa, The Democratic Republic of Congo.
Pius Kabututu ZakayiFaculty of Medicine, Department of Basic Sciences, Molecular Biology Service, University of Kinshasa, Kinshasa, The Democratic Republic of Congo.
Alex KaMolecular Mycology Research Laboratory, Faculty of Medicine and Health, Centre for Infectious Diseases and Microbiology, Sydney Medical School, Westmead Clinical School, Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Westmead Hospital-Research and Education Network, Westmead Institute for Medical Research, Sydney, Australia.
Marcel Mbula MambimbiFaculty of Medicine, Department of Internal Medicine/Department of Tropical Medicine, Infectious Diseases Service, University of Kinshasa, Kinshasa, The Democratic Republic of Congo.
Gaultier MuendeleInternal Medicine Department, Advanced HIV Disease Management Unit, Centre Hospitalier Mère et Enfant de NGABA, Kinshasa, The Democratic Republic of Congo.
Raphael BoreuxCentre for Interdisciplinary Research on Medicines, University of Liege, Liege, Belgium.
Nicole LanduInternal Medicine Department, Advanced HIV Disease Management Unit, Centre Médical et Evangélique Révérend LUYINDU, Kinshasa, The Democratic Republic of Congo.
Celestin Nzanzu MudogoFaculty of Medicine, Department of Basic Sciences, Molecular Biology Service, University of Kinshasa, Kinshasa, The Democratic Republic of Congo.
Pierre-Robert M'BuzeInternal Medicine Department, Advanced HIV Disease Management Unit, Centre Hospitalier Roi Baudouin 1er, Kinshasa, The Democratic Republic of Congo.
Michel MoutschenDepartment of Infectious Diseases and General Internal Medicine, University Hospital Centre of Liege, Liege, Belgium.
Wieland MeyerMolecular Mycology Research Laboratory, Faculty of Medicine and Health, Centre for Infectious Diseases and Microbiology, Sydney Medical School, Westmead Clinical School, Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Westmead Hospital-Research and Education Network, Westmead Institute for Medical Research, Sydney, Australia.
Georges Mvumbi LeloFaculty of Medicine, Department of Basic Sciences, Molecular Biology Service, University of Kinshasa, Kinshasa, The Democratic Republic of Congo.
Marie-Pierre HayetteCentre for Interdisciplinary Research on Medicines, University of Liege, Liege, Belgium.ORCID 0000-0002-9025-6493
University of Kinshasa · CDUniversity of Liège · BEKinshasa General Hospital · CDThe University of Sydney · AUCentre Hospitalier Universitaire de Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuromeningeal cryptococcosis (NMC) is a life-threatening opportunistic infection in advanced HIV disease patients (AHDP). It is caused by Cryptococcus spp. complexes and mainly occurs in sub-Saharan Africa. In this study, we performed molecular characterization and antifungal susceptibility profiling of Cryptococcus isolates from AHDP in Kinshasa (DRC). Additionally, we investigated a possible association between NMC severity factors and the Cryptococcus neoformans (Cn) multilocus sequence typing (MLST) profiles. We characterized the isolates using PCR serotyping, MALDI-TOF MS, internal transcribed spacer (ITS) sequencing, and MLST. Susceptibility testing for the major antifungal drugs was performed according to the EUCAST guidelines. Parameters associated with NMC severity, such as hypoglycorrhachia (< 50 mg/dL), increased cerebral spinal fluid opening pressure (> 30 cm H2O), and poor therapeutic outcome were compared with the Cn MLST sequences type (ST). Twenty-three out of 29 Cryptococcus isolates were identified as serotype A using PCR serotyping (79.3%; 95% IC: 65.5-93.1), while six (20.7%; 95% IC: 6.9-34.5) were not serotypable. The 29 isolates were identified by ITS sequencing as follows: Cryptococcus neoformans (23/29, 79.3%), Cutaneotrichosporon curvatus (previously called Cryptococcus curvatus) (5/29, 17.2%), and Papiliotrema laurentii (Cryptococcus laurentii) (1/29, 3.5%). Using the ISHAM MLST scheme, all Cn isolates were identified as molecular type VNI. These comprised seven different STs: ST93 (n = 15), ST5 (n = 2), ST53 (n = 1), ST31 (n = 1), ST4 (n = 1), ST69 (n = 1), and one novel ST that has not yet been reported from other parts of the world and was subsequently assigned as ST659 (n = 2). Of the included strains, only Papiliotrema laurentii was resistant to amphoterin B (1/29, 3.5%), 6.8% (2/29) were resistant to 5-flucytosine (the single Papiliotrema laurentii strain and one Cryptococcus neoformans isolate), and 13.8% (4/29) to fluconazole, including two of five (40%) Cutaneotrichosporon curvatus and two of 23 (8.7%) C. neoformans strains. We found a significative association between poor therapeutic outcome and a non-ST93 sequence type of causative strains (these concerned the less common sequence types: ST53, ST31, ST5, ST4, ST659, and ST69) (87.5% versus 40%, p = 0.02). Molecular analysis of Cryptococcus spp. isolates showed a wide species diversity and genetic heterogenicity of Cn within the VNI molecular type. Furthermore, it is worrying that among included strains we found resistances to several of the commonly used antifungals.

Indexed as

CryptococcosisCryptococcus neoformansHIV InfectionsAntifungal AgentsBasidiomycotaDemocratic Republic of the CongoGenetic VariationGenotypeHumansMultilocus Sequence TypingMycological Typing TechniquesAntifungal Agents

Identifiers

PMID35587939
PMCPMC9119562
OpenAlexW4280555609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.